PhotoMedex and Galderma Laboratories, LP, have entered into a co-promotion agreement for Galderma’s photodynamic therapy application for the treatment of actinic keratoses (AKs). Under the terms of the agreement, the sales force at PhotoMedex will promote Galderma’s drug methyl aminolevulinate Cream 16.8% (Metvixia) and Galderma’s light-emitting diode (Aktilite CL128 LED) lamp to healthcare professionals, including dermatologists, plastic surgeons and cosmetic surgeons throughout the United States. Galderma will provide marketing support and distribution.
The 3-year agreement begins in January; no financial terms have been disclosed. Metvixia is a topical porphyrin precursor used in photodynamic therapy. When applied to AK lesions, Metvixia is selectively absorbed into precancerous cells causing a build-up of endogenous porphyrins, according to the company. These endogenous porphyrins are illuminated with the Aktilite CL128 lamp emitting a narrow output spectrum of red light with a peak wavelength at 630 nm. Subsequently, a reaction occurs that results in the destruction of the precancerous cells. Clinical trials in various countries with the Metvixia PDT system have shown comparable or better response rates than conventional treatments, such as cryotherapy or surgery, according to a company press release. Metvixia PDT selectively targets precancerous cells so the surrounding healthy cells are less subjected to the treatment, resulting in minimized scarring.
In clinical trials, the most commonly reported adverse events associated with use of Metvixia PDT were contact sensitization, erythema, pain, burning and skin discomfort/irritation.
